

## 免疫学

### 学術論文

- 1) Harada M, Ishihara Y, Itoh K, Yamanaka R. Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in HLA-A24<sup>+</sup> glioma patients. **Oncology Reports**, 17: 629-636, 2007.
- 2) Eto M, Harano M, Tatsugami K, Harada M, Kamiryo Y, Kiyoshima K, Hamaguchi M, Tsuneyoshi M, Yoshikai Y, Naito S. Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease. **Clinical Cancer Research**, 13: 1029-1035, 2007.
- 3) Komohara Y, Harada M, Arima Y, Suekane S, Noguchi M, Yamada A, Itoh K, Matsuoka K. Identification of target antigens in specific immunotherapy for renal cell carcinoma. **Journal of Urology**, 177: 1157-1162, 2007.
- 4) Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. **Cancer Immunology Immunotherapy**, 56: 689-698, 2007.
- 5) Matsueda S, Takedatsu H, Sasada T, Azuma K, Noguchi M, Shichijo S, Itoh K, Harada M. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles. **Journal of Immunotherapy**, 30: 274-281, 2007.
- 6) Noguchi M, Mine T, Yamada A, Obata Y, Yoshida K, Mizoguchi J, Harada M, Suekane S, Itoh K, Matsuoka K. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: An analysis of prognostic factors in the treatment. **Oncology Research**, 16: 341-349, 2007.
- 7) Noguchi M, Yao A, Harada M, Nakashima O, Itoh K, Matsuoka K. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. **Prostate**, 67, 933-942, 2007.
- 8) Sato Y, Fujiwara T, Mine T, Shomura H, Homma S, Maeda Y, Tokunaga N, Ikeda Y, Ishida Y, Yamada A, Tanaka N, Itoh K, Harada M, Todo S. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. **Cancer Science**, 98: 1113-1119, 2007.
- 9) Homma S, Komohara Y, Harada M, Saya H, Todo S, Itoh K, Noguchi M. Differential levels of human leukocyte antigen-class I, multidrug-resistance 1 and androgen receptor expressions in untreated prostate cancer cells: The robustness of

- prostate cancer. **Oncology Reports**, 18: 343-346, 2007.
- 10) Itoh Y, Komohara Y, Komatsu N, Minami T, Saito K, Noguchi M, Itoh K, Harada M. New peptides of the polycomb group protein enhancer of zeste homolog 2 (EZH2) with the potential to induce cancer-reactive cytotoxic T lymphocytes in HLA-A2<sup>+</sup> prostate cancer patients. **Oncology Reports**, 18: 1231-1237, 2007.
  - 11) Komohara Y, Harada M, Ishihara Y, Suekane S, Noguchi M, Yamada A, Matsuoka K, Itoh K. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. **Oncology Reports**, 18: 1463-1468, 2007.
  - 12) Naito M, Komohara Y, Ishihara Y, Noguchi M, Yamashita Y, Shirakusa T, Yamada A, Itoh K, Harada M. Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. **British Journal of Cancer**, 97: 1648-1654, 2007.
  - 13) \*Takahashi Y, \*Harashima N, Kajigaya S, Yokoyama H, Cherkasova E, McCoy Jr. P, Hanada K, Mena O, Kurlander R, Tawab A, Srinivasan R, Lundqvist A, Malinzak E, Geller N, Lerman MI, Childs RW. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. (\*These authors contributed equally to this work.) **Journal of Clinical Investigation**, 118: 1099-1109, 2008.
  - 14) Eto M, Kamiryō Y, Takeuchi A, Harano M, Tatsugami K, Harada M, Kiyoshima K, Hamaguchi M, Teshima T, Tsuneyoshi M, Yoshikai Y, Naito S. Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor. **Clinical Cancer Research**, 14: 2833-2840, 2008.
  - 15) Jin M, Komohara Y, Shichijo S, Harada M, Yamanaka R, Miyamoto S, Nikawa J, Itoh K, Yamada A. Identification of Eph6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24<sup>+</sup> malignant glioma patients. **Oncology Reports**, 19: 1277-1283, 2008.
  - 16) Komatsu N, Harada M, Nakagawa M, Tanaka Y, Ono T, Gohara S, Ohkubo K, Itoh K. A correlation between symptom severity and unbalanced reactive IgA production in Japanese cedar pollinosis patients. **Asian Pacific Journal of Allergy and Immunology**, 26: 97-104, 2008.

#### 学会発表

- 1) Nanae Harashima, Yukiko Shimizu, Ayako Takamori, Kiyoshi Kurihara, Atae Utsunomiya, Ryuji Tanosaki, Masato Masuda, Jun Okamura, Mari Kannagi. Positive Conversion of Tax-specific CTL response in ATL patients after hematopoietic stem cell transplantation. The 13<sup>th</sup> International Conference on

- Human Retrovirology: HTLV and Related Viruses, Hakone, Japan, May 22 - 25, 2007.
- 2) Ayako Takamori, Kiyoshi Kurihara, Yukiko Shimizu, Nanae Harashima, Ilseung Choi, Naokuni Uike, Ryuji Tanosaki, Atae Utsunomiya, Jun Okamura, and Mari Kannagi. Presence of Tax-specific cytotoxic T lymphocytes in Adult T-cell leukemia patients and their functional failure. The 13<sup>th</sup> International Conference on Human Retrovirology: HTLV and Related Viruses, Hakone, Japan, May 22 - 25, 2007.
  - 3) Yukiko Shimizu, Kiyoshi Kurihara, Ayako Takamori, Nanae Harashima, Atae Utsunomiya, Jun Okamura, Kazuo Nishigaki, Takao Masuda, and Mari Kannagi. Diversity in Tax-specific T-cell responses among asymptomatic HTLV-I carriers. The 13<sup>th</sup> International Conference on Human Retrovirology: HTLV and Related Viruses, Hakone, Japan, May 22 - 25, 2007.
  - 4) Masatoshi Eto, Mamoru Harada, Masahiko Harano, Katsunori Tatsugami, Yoriyuki Kamiryō, Ario Takeuchi, Yasunobu Yoshikai, Seiji Naito. Vaccination of donors with tumor antigen peptides enhances antitumor effects in nonmyeloablative allogeneic cell therapy. 第 66 回日本癌学会総会, 横浜, 2007 年 10 月 3 - 5 日.
  - 5) Mari Kannagi, Yukiko Shimizu, Ayako Takamori, Kiyoshi Kurihara, Nanae Harashima, Atae Utsunomiya. Insufficient HTLV-I-specific T-cell response as an ATL risk factor. 第 66 回日本癌学会学術総会, 横浜, 2007 年 10 月 3 - 5 日.
  - 6) Nanae Harashima, Yukiko Shimizu, Ayako Takamori, Atae Utsunomiya, Ryuji Tanosaki, Jun Okamura, Mari Kannagi. Detection of circulating Tax-specific CTL by tetramers and *in vitro* induction of the CTL from post-HSCT ATL patients. 第 66 回日本癌学会学術総会, 横浜, 2007 年 10 月 3 - 5 日.
  - 7) Mamoru Harada, Nanae Harashima. Evidence of the extrathymic development of tyrosinase-related protein (TRP)2-recognizing CD8<sup>+</sup> T cells with low avidity. 第 37 回日本免疫学会総会, 東京, 2007 年 11 月 20 - 22 日.
  - 8) 原嶋奈々江、高橋義行、原田守、Richard Childs. 同種造血幹細胞移植後の腎細胞癌患者由来 T 細胞が認識する新規腫瘍抗原の同定とその発現. 第 12 回基盤的癌免疫研究会総会, 埼玉, 2008 年 7 月 2 - 3 日.
  - 9) 神奈木真理、清水由紀子、高森絢子、長谷川温彦、宇都宮與、田野崎隆二、山野嘉久、高塚奈津子、小森一哉、栗原清、原嶋奈々江、渡辺俊樹、菱澤方勝、栗村真由美、岡村純. ATL およびその前段階における Tax 特異的 T 細胞の低応答性: 免疫学的 ATL 危険因子とその回避. 第 1 回 HTLV-1 研究会, 東京, 2008 年 8 月 23 - 24 日.
  - 10) 頓宮美樹、原嶋奈々江、原田孝之、原田守. Cyclophosphamide と adriacycin による抗がん免疫応答の増強. 第 67 回日本癌学会学術総会, 名古屋, 2008 年

10月28 - 30日.

- 11) 高橋義行、原嶋奈々江、小島勢二、Richard Childs. 同種造血幹細胞移植後の腎細胞癌患者由来T細胞が認識するHERV-E由来新規腫瘍抗原CT-RCCの同定とその発現解析. 第67回日本癌学会学術総会, 名古屋, 2008年10月28 - 30日.
- 12) 清水由紀子、高森絢子、宇都宮與、栗村真由美、山野嘉久、菱澤方勝、原嶋奈々江、長谷川温彦、渡辺俊樹、岡村純、増田貴夫、神奈木真理. 一部のHTLV-Iキャリアとくすぶり型ATLはTax特異的T細胞応答の減弱と高プロウイルス量を示す. 第67回日本癌学会学術総会, 名古屋, 2008年10月28 - 30日.
- 13) Masahiro Kondo, Nanae Harashima, Yoko Murakawa, Mamoru Harada. Roles of pro-inflammatory cytokines and Fas in the pathogenesis of inflammatory myopathies. 第38回日本免疫学会総会, 京都, 2008年12月1 - 3日.
- 14) Yukiko Shimizu, Ayako Takamori, Atae Utsunomiya, Mayumi Kurimura, Yoshihisa Yamano, Masakatsu Hishizawa, Atsuhiko Hasegawa, Kiyoshi Kurihara, Nanae Harashima, Toshiki Watanabe, Jun Okamura, Takao Masuda, Mari Kannagi. 成人T細胞白血病の免疫学的リスクファクター. 第38回日本免疫学会総会, 京都, 2008年12月1 - 3日.